To develop a new high-resolution (HR)CT abnormalities quantification tool (CVILDES) for interstitial lung diseases (ILDs) based on the nnU-Net network structure and to determine whether the quantitative parameters derived from this new software could offer a reliable and precise assessment in a clinical setting that is in line with expert visual evaluation. HRCT scans from 83 cases of ILDs and 20 cases of other diffuse lung diseases were labeled section by section by multiple radiologists and were used as training data for developing a deep learning model based on nnU-Net, employing a supervised learning approach. For clinical validation, a cohort including 51 cases of interstitial pneumonia with autoimmune features (IPAF) and 14 cases of idiopathic pulmonary fibrosis (IPF) had CT parenchymal patterns evaluated quantitatively with CVILDES and by visual evaluation. Subsequently, we assessed the correlation of the two methodologies for ILD features quantification. Furthermore, the correlation between the quantitative results derived from the two methods and pulmonary function parameters (DL_CO%, FVC%, and FEV%) was compared. All CT data were successfully quantified using CVILDES. CVILDES-quantified results (total ILD extent, ground-glass opacity, consolidation, reticular pattern and honeycombing) showed a strong correlation with visual evaluation and were numerically close to the visual evaluation results (r = 0.64-0.89, p < 0.0001), particularly for the extent of fibrosis (r = 0.82, p < 0.0001). As judged by correlation with pulmonary function parameters, CVILDES quantification was comparable or even superior to visual evaluation. nnU-Net-based CVILDES was comparable to visual evaluation for ILD abnormalities quantification. Question Visual assessment of ILD on HRCT is time-consuming and exhibits poor inter-observer agreement, making it challenging to accurately evaluate the therapeutic efficacy. Findings nnU-Net-based Computer vision-based ILD evaluation system (CVILDES) accurately segmented and quantified the HRCT features of ILD, and results were comparable to visual evaluation. Clinical relevance This study developed a new tool that has the potential to be applied in the quantitative assessment of ILD.

This study proposes a novel approach to predict the efficacy of bevacizumab (BEV) in treating peritumoral edema in metastatic brain tumor patients by integrating advanced machine learning (ML) techniques with comprehensive imaging and clinical data. A retrospective analysis was performed on 300 patients who received BEV treatment from September 2013 to January 2024. The dataset incorporated 13 predictive features: 8 clinical variables and 5 radiological variables. The dataset was divided into a training set (70%) and a test set (30%) using stratified sampling. Data preprocessing was carried out through methods such as handling missing values with the MICE method, detecting and adjusting outliers, and feature scaling. Four algorithms, namely Random Forest (RF), Logistic Regression, Gradient Boosting Tree, and Naive Bayes, were selected to construct binary classification models. A tenfold cross-validation strategy was implemented during training, and techniques like regularization, hyperparameter optimization, and oversampling were used to mitigate overfitting. The RF model demonstrated superior performance, achieving an accuracy of 0.89, a precision of 0.94, F1-score of 0.92, with both AUC-ROC and AUC-PR values reaching 0.91. Feature importance analysis consistently identified edema volume as the most significant predictor, followed by edema index, patient age, and tumor volume. Traditional multivariate logistic regression corroborated these findings, confirming that edema volume and edema index were independent predictors (p < 0.01). Our results highlight the potential of ML-driven predictive models in optimizing BEV treatment selection, reducing unnecessary treatment risks, and improving clinical decision-making in neuro-oncology.

Critical findings in radiology reports are life threatening conditions that need to be communicated promptly to physicians for timely management of patients. Although challenging, advancements in natural language processing (NLP), particularly large language models (LLMs), now enable the automated identification of key findings from verbose reports. Given the scarcity of labeled critical findings data, we implemented a two-phase, weakly supervised fine-tuning approach on 15,000 unlabeled Mayo Clinic reports. This fine-tuned model then automatically extracted critical terms on internal (Mayo Clinic, n = 80) and external (MIMIC-III, n = 123) test datasets, validated against expert annotations. Model performance was further assessed on 5000 MIMIC-IV reports using LLM-aided metrics, G-eval and Prometheus. Both manual and LLM-based evaluations showed improved task alignment with weak supervision. The pipeline and model, publicly available under an academic license, can aid in critical finding extraction for research and clinical use ( https://github.com/dasavisha/CriticalFindings_Extract ).

The study of the human phenome is essential for understanding the complexities of wellness and disease and their transitions, with molecular imaging being a vital tool in this exploration. Molecular imaging embodies the 4 principles of human phenomics: precise measurement, accurate calculation or analysis, well-controlled manipulation or intervention, and innovative invention or creation. Its application has significantly enhanced the precision, individualization, and effectiveness of medical interventions. This article provides an overview of molecular imaging's technologic advancements and presents the potential use of molecular imaging in human phenomics and precision medicine. The integration of molecular imaging with multiomics data and artificial intelligence has the potential to transform health care, promoting proactive and preventive strategies. This evolving approach promises to deepen our understanding of the human phenome, lead to preclinical diagnostics and treatments, and establish quantitative frameworks for precision health management.

High-grade gliomas, particularly glioblastoma (MeSH:Glioblastoma), are among the most aggressive and lethal central nervous system tumors, necessitating advanced diagnostic and prognostic strategies. This systematic review and epistemic meta-analysis explore the integration of Artificial Intelligence (AI) and Radiomics Inter-field (AIRI) to enhance predictive modeling for tumor progression. A comprehensive literature search identified 19 high-quality studies, which were analyzed to evaluate radiomic features and machine learning models in predicting overall survival (OS) and progression-free survival (PFS). Key findings highlight the predictive strength of specific MRI-derived radiomic features such as log-filter and Gabor textures and the superior performance of Support Vector Machines (SVM) and Random Forest (RF) models, achieving high accuracy and AUC scores (e.g., 98% AUC and 98.7% accuracy for OS). This research demonstrates the current state of the AIRI field and shows that current articles report their results with different performance indicators and metrics, making outcomes heterogenous and hard to integrate knowledge. Additionally, it was explored that today some articles use biased methodologies. This study proposes a structured AIRI development roadmap and guidelines, to avoid bias and make results comparable, emphasizing standardized feature extraction and AI model training to improve reproducibility across clinical settings. By advancing precision medicine, AIRI integration has the potential to refine clinical decision-making and enhance patient outcomes.

In this study, we propose a novel approach to enhancing transfer learning by optimizing data selection through deep learning techniques and corresponding innovative learning strategies. This method is particularly beneficial when the available dataset has reached its limit and cannot be further expanded. Our approach focuses on maximizing the use of existing data to improve learning outcomes which offers an effective solution for data-limited applications in medical imaging classification. The proposed method consists of two stages. In the first stage, an original network performs the initial classification. When the original network exhibits low confidence in its predictions, ambiguous classifications are passed to a secondary decision-making step involving a newly trained network, referred to as the True network. The True network shares the same architecture as the original network but is trained on a subset of the original dataset that is selected based on consensus among multiple independent networks. It is then used to verify the classification results of the original network, identifying and correcting any misclassified images. To evaluate the effectiveness of our approach, we conducted experiments using thyroid nodule ultrasound images with the ResNet101 and Vision Transformer architectures along with eleven other pre-trained neural networks. The proposed method led to performance improvements across all five key metrics, accuracy, sensitivity, specificity, F1-score, and AUC, compared to using only the original or True networks in ResNet101. Additionally, the True network showed strong performance when applied to the Vision Transformer and similar enhancements were observed across multiple convolutional neural network architectures. Furthermore, to assess the robustness and adaptability of our method across different medical imaging modalities, we applied it to dermoscopic images and observed similar performance enhancements. These results provide evidence of the effectiveness of our approach in improving transfer learning-based medical image classification without requiring additional training data.

Uncertainty assessment of deep learning autosegmentation (DLAS) models can support contour corrections in adaptive radiotherapy (ART), e.g. by utilizing Monte Carlo Dropout (MCD) uncertainty maps. However, poorly calibrated uncertainties at the patient level often render these clinically nonviable. We evaluated population-based and patient-specific DLAS accuracy and uncertainty calibration and propose a patient-specific post-training uncertainty calibration method for DLAS in ART.&#xD;&#xD;Approach. The study included 122 lung cancer patients treated with a low-field MR-linac (80/19/23 training/validation/test cases). Ten single-label 3D-U-Net population-based baseline models (BM) were trained with dropout using planning MRIs (pMRIs) and contours for nine organs-at-riks (OARs) and gross tumor volumes (GTVs). Patient-specific models (PS) were created by fine-tuning BMs with each test patient's pMRI. Model uncertainty was assessed with MCD, averaged into probability maps. Uncertainty calibration was evaluated with reliability diagrams and expected calibration error (ECE). A proposed post-training calibration method rescaled MCD probabilities for fraction images in BM (calBM) and PS (calPS) after fitting reliability diagrams from pMRIs. All models were evaluated on fraction images using Dice similarity coefficient (DSC), 95th percentile Hausdorff distance (HD95) and ECE. Metrics were compared among models for all OARs combined (n=163), and the GTV (n=23), using Friedman and posthoc-Nemenyi tests (α=0.05).&#xD;&#xD;Main results. For the OARs, patient-specific fine-tuning significantly (p<0.001) increased median DSC from 0.78 (BM) to 0.86 (PS) and reduced HD95 from 14mm (BM) to 6.0mm (PS). Uncertainty calibration achieved substantial reductions in ECE, from 0.25 (BM) to 0.091 (calBM) and 0.22 (PS) to 0.11 (calPS) (p<0.001), without significantly affecting DSC or HD95 (p>0.05). For the GTV, BM performance was poor (DSC=0.05) but significantly (p<0.001) improved with PS training (DSC=0.75) while uncertainty calibration reduced ECE from 0.22 (PS) to 0.15 (calPS) (p=0.45).&#xD;&#xD;Significance. Post-training uncertainty calibration yields geometrically accurate DLAS models with well-calibrated uncertainty estimates, crucial for ART applications.

The choroid plexus (ChP) plays a pivotal role in inflammatory processes that occur in multiple sclerosis (MS). The enlargement of the ChP in relapsing-remitting multiple sclerosis (RRMS) is considered to be an indication of disease activity and has been associated with periventricular remyelination failure. This cross-sectional study aimed to identify the relationship between ChP and periventricular tissue damage which occurs in MS, and to elucidate the role of neuroinflammation in primary progressive multiple sclerosis (PPMS). ChP volume was assessed by a novel deep learning segmentation method based on structural MRI data acquired from two centers. In total, 141 RRMS and 64 PPMS patients were included, along with 75 healthy control subjects. In addition, T1w/FLAIR ratios were calculated within periventricular bands to quantify microstructural tissue damage and to assess its relationship to ChP volume. When compared to healthy controls, ChP volumes were significantly increased in RRMS, but not in patients with PPMS. T1w/FLAIR ratios in the normal appearing white matter (NAWM) showing periventricular gradients were decreased in patients with multiple sclerosis when compared to healthy control subjects and lower T1w/FLAIR ratios radiating out from the lateral ventricles were found in patients with PPMS. A relationship between ChP volume and T1w/FLAIR ratio in NAWM was found within the inner periventricular bands in RRMS patients. A longer duration of disease was associated with larger ChP volumes only in RRMS patients. Enlarged ChP volumes were also significantly associated with reduced cortex volumes and increased lesion volumes in RRMS. Our analysis confirmed that the ChP was significantly enlarged in patients with RRMS, which was related to brain lesion volumes and which suggested a dynamic development as it was associated with disease duration. Plexus enlargement was further associated with periventricular demyelination or tissue damage assessed by T1w/FLAIR ratios in RRMS. Furthermore, we did not find an enlargement of the ChP in patients with PPMS, possibly indicating the reduced involvement of inflammatory processes in the progressive phase of MS. The association between enlarged ChP volumes and cortical atrophy in RRMS highlighted the vulnerability of structures close to the CSF.

Phyllodes tumors (PTs) are rare breast tumors with high recurrence rates, current methods relying on post-resection pathology often delay detection and require further surgery. We propose a deep-learning-based Phyllodes Tumors Hierarchical Diagnosis Model (PTs-HDM) for preoperative identification and grading. Ultrasound images from five hospitals were retrospectively collected, with all patients having undergone surgical pathological confirmation of either PTs or fibroadenomas (FAs). PTs-HDM follows a two-stage classification: first distinguishing PTs from FAs, then grading PTs into benign or borderline/malignant. Model performance metrics including AUC and accuracy were quantitatively evaluated. A comparative analysis was conducted between the algorithm's diagnostic capabilities and those of radiologists with varying clinical experience within an external validation cohort. Through the provision of PTs-HDM's automated classification outputs and associated thermal activation mapping guidance, we systematically assessed the enhancement in radiologists' diagnostic concordance and classification accuracy. A total of 712 patients were included. On the external test set, PTs-HDM achieved an AUC of 0.883, accuracy of 87.3% for PT vs. FA classification. Subgroup analysis showed high accuracy for tumors < 2 cm (90.9%). In hierarchical classification, the model obtained an AUC of 0.856 and accuracy of 80.9%. Radiologists' performance improved with PTs-HDM assistance, with binary classification accuracy increasing from 82.7%, 67.7%, and 64.2-87.6%, 76.6%, and 82.1% for senior, attending, and resident radiologists, respectively. Their hierarchical classification AUCs improved from 0.566 to 0.827 to 0.725-0.837. PTs-HDM also enhanced inter-radiologist consistency, increasing Kappa values from - 0.05 to 0.41 to 0.12 to 0.65, and the intraclass correlation coefficient from 0.19 to 0.45. PTs-HDM shows strong diagnostic performance, especially for small lesions, and improves radiologists' accuracy across all experience levels, bridging diagnostic gaps and providing reliable support for PTs' hierarchical diagnosis.

Radiologists' eye movements during medical image interpretation reflect their perceptual-cognitive processes of diagnostic decisions. The eye movement data can be modeled to represent clinically relevant regions in a medical image and potentially integrated into an artificial intelligence (AI) system for automatic diagnosis in medical imaging. In this article, we first conduct a large-scale eye-tracking study involving 13 radiologists interpreting 191 chest X-ray (CXR) images, establishing a best-of-its-kind CXR visual saliency benchmark. We then perform analysis to quantify the reliability and clinical relevance of saliency maps (SMs) generated for CXR images. We develop CXR image saliency prediction method (CXRSalNet), a novel saliency prediction model that leverages radiologists' gaze information to optimize the use of unlabeled CXR images, enhancing training and mitigating data scarcity. We also demonstrate the application of our CXR saliency model in enhancing the performance of AI-powered diagnostic imaging systems.